Volume 23 Issue 2
Feb.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(2): 309-313
YU Jiajia, LIU Meng, WANG Xiaoqiang, QIU Sha, ZHANG Yunjie. Exploring the medication patterns of gastroesophageal reflux disease and the application of toxic traditional Chinese medicine using data mining of ancient Chinese medicine texts[J]. Chinese Journal of General Practice, 2025, 23(2): 309-313. doi: 10.16766/j.cnki.issn.1674-4152.003892
Citation: YU Jiajia, LIU Meng, WANG Xiaoqiang, QIU Sha, ZHANG Yunjie. Exploring the medication patterns of gastroesophageal reflux disease and the application of toxic traditional Chinese medicine using data mining of ancient Chinese medicine texts[J]. Chinese Journal of General Practice, 2025, 23(2): 309-313. doi: 10.16766/j.cnki.issn.1674-4152.003892
shu

Exploring the medication patterns of gastroesophageal reflux disease and the application of toxic traditional Chinese medicine using data mining of ancient Chinese medicine texts

doi: 10.16766/j.cnki.issn.1674-4152.003892
  • 1.

    Department of Traditional Chinese Medicine, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, Shandong 266042, China

Funds:

 2021Z043

 2020-WJZD070

  • Received Date: 2024-06-19
    Available Online: 2025-03-27
    Abstract
  •   Objective   To investigate the medicinal concepts and compatibility principles in ancient Chinese medicine for treating gastroesophageal reflux disease, and to explore the application of toxic traditional Chinese medicine (TCM) in the treatment of gastroesophageal reflux disease based on ancient Chinese medicine prescriptions.   Methods   A total of 13 211 references were reviewed, and 988 prescriptions were selected, including 315 TCM flavors, with a cumulative usage frequency of 8 375. Twenty-eight drugs were used more than 80 times, with 41 drugs in total. Of these, 598 prescriptions containing toxic TCM were used, accounting for 60.53% of all prescriptions. The four qualities (Qi) are mainly warming. The five flavors (Wei) are mainly pungent. The spleen and stomach were the main channels targeted, followed by the lung, heart, and liver. the efficacy of the drugs was the highest in tonifying deficiency drugs, followed by qi-regulating drugs and warming interior drugs. According to the association rules, 5 pairs of medicines and 10 groups of corner medicines were identified, among which Chenpi, Banxia, ginger, licorice, Poria cocos, Atractylodes macrocephala, and ginseng are the core medicines in ancient texts to treat gastroesophageal reflux disease. Cluster analysis identified 6 new drug groups in prescriptions.   Conclusion   In ancient times, doctors primarily used warming and pungent medications for treating gastroesophageal reflux disease, focusing on tonifying qi, strengthening spleen, and warming the middle. Treatment targeted regulating qi, promoting qi circulation, and eliminating dampness and phlegm. In the later stages of the disease, alongside tonifying deficiency, the application of traditional Chinese medicines for attacking toxins, breaking up accumulation, and eliminating toxic tumors was emphasized.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    中国医疗保健国际交流促进会胃食管反流病学分会. 中国胃食管反流病多学科诊疗共识2022(一)[J]. 中华胃食管反流病电子杂志, 2022, 9(2): 51-86.

    Gastroesophageal Reflux Disease Branch of China Association for International Exchange and Promotion of Healthcare. Multidisciplinary consensus on the diagnosis and treatment of gastroesophageal reflux disease in China 2022 (1)[J]. Chin J Gastroesophagol Reflux Dis (Electronic Edition), 2022, 9(2): 51-86.
    [2]
    房子铭, 谢晶日, 孙志文. 中医药治疗胃食管反流病机制的研究进展[J]. 中医药信息, 2022, 39(12): 81-85.

    FANG Z M, XIE J R, SUN Z W. Research progress on the mechanism of traditional Chinese medicine in treating gastroesophageal reflux disease[J]. Information of Chinese Medicine, 2022, 39(12): 81-85.
    [3]
    中华中医药学会. 中华医典[M]. 5版. 长沙: 湖南电子音像出版社, 2014.

    China Association of Chinese Medicine. Chinese Medical Code[M]. 5th edition. Hunan: Hunan Electronic Audio Visual Publishing House, 2014.
    [4]
    李开楊, 蔺晓源, 赵琦, 等. 基于名医经验的反流性食管炎中医病名、病因病机、证候分型研究[J]. 山西中医, 2022, 38(10): 51-54.

    LI K Y, LIN X Y, ZHAO Q, et al. Research on Traditional Chinese Medicine Disease Names, Etiology, Pathogenesis, and Syndrome Classification of Reflux Esophagitis Based on the Experience of Famous Doctors[J]. Shanxi Journal of Traditional Chinese Medicine, 2022, 38(10): 51-54.
    [5]
    中华中医药学会脾胃病分会. 胃食管反流病中医诊疗专家共识(2023)[J]. 中医杂志, 2023, 64(18): 1935-1944.

    Spleen and Stomach Disease Branch of the Chinese Association of Traditional Chinese Medicine. Consensus of Traditional Chinese Medicine Diagnosis and Treatment Experts on Gastroesophageal Reflux Disease(2023)[J]. Journal of Traditional Chinese Medicine, 2023, 64(18): 1935-1944.
    [6]
    国家药典委员会. 中华人民共和国药典[M]. 北京: 中国医药科技出版社, 2020.

    State Pharmacopoeia Committee. Pharmacopoeia of the people 's republic of china[M]. Beijing: China Pharmaceutical Science and Technology Press, 2020.
    [7]
    南京中医药大学. 中药大辞典[M]. 2版. 上海: 上海科学技术出版社, 2006.

    Nanjing University of Chinese Medicine. Dictionary of Traditional Chinese Pharmacy[M]. 2nd Edition. Shanghai: Shanghai Science and Technology Press, 2006.
    [8]
    钟赣生, 杨柏灿. 中药学[M]. 北京: 中国中医药出版社, 2021.

    ZHONG G S, YANG B C. Traditional Chinese Medicine[M]. Beijing: China Traditional Chinese Medicine Press, 2021.
    [9]
    胡祥鹏, 张深深, 王乔, 等. 胃食管反流病重叠消化不良的临床及精神心理特征研究[J]. 中华全科医学, 2019, 17(9): 1447-1550. doi: 10.16766/j.cnki.issn.1674-4152.000966

    HU X P, ZHANG S S, WANG Q, et al. Clinical and psychological characteristics of overlapping dyspepsia in patients with gastroesophageal reflux disease[J]. Chinese Journal of General Practice, 2019, 17(9): 1447-1550. doi: 10.16766/j.cnki.issn.1674-4152.000966
    [10]
    宋茜雯. 艾司奥美拉唑联合氟哌噻吨美利曲辛治疗难治性胃食管反流病患者的疗效[J]. 实用临床医药杂志, 2019, 23(3): 78-81.

    SONG Q W. Efficiency of esomeprazole combined with flupentixol-melitracen in the treatment of patients with refractory gastroesophageal reflux disease[J]. J Pra Cli Med, 2019, 23(3): 78-81.
    [11]
    徐明瑶, 黎丽群, 刘鑫, 等. NF-κB信号通路在"反流性食管炎-食管癌"中的作用及中药干预研究进展[J]. 中国实验方剂学杂志, 2024, 30(2): 221-233.

    XU M Y, LI L Q, LIU X, et al. Role of NF-κB Signaling Pathway in "Reflux Esophagitis-esophageal Cancer" and Traditional Chinese Medicine Intervention: A Review[J]. Chinese Journal of Experimental Formulae, 2024, 30(2): 221-233.
    [12]
    王旭红, 刘改霞, 李耀辉, 等. 基于网络药理学探寻β-谷甾醇的作用机制[J]. 世界中医药, 2022, 17(2): 172-176.

    WANG X H, LIU G X, LI Y H, et al. Mechanism of β-Sitosterol Based on Network Pharmacology[J]. World of Chinese Medicine, 2022, 17(2): 172-176.
    [13]
    陈丽君, 李翠娟, 巩振东, 等. 半夏临床用量及毒性分析[J]. 山东中医杂志, 2020, 39(3): 298-301.

    CHEN L J, LI C J, GONG Z D, et al. Clinical Dosage andToxicityAnalysis of Banxia[J]. Shandong Journal of Traditional Chinese Medicine, 2020, 39(3): 298-301.
    [14]
    WANG L Y, YEH S L, HSU S T, et al. The Anti proliferative and apoptotic effects of rutaecarpine on human esophageal squamous cell carcinoma cell line CE81T/VGH in vitro and in vivo[J]. Int J Mol Sci, 2022, 23(5): 2843. DOI: 10.3390/ijms23052843.
    [15]
    张鹏, 毕超然, 朴春丽. 吴茱萸的临床应用及其用量探究[J]. 吉林中医药, 2019, 39(2): 177-180.

    ZHANG P, BI C R, DU C L. Exploration about the Clinical Application and Dosage of Evodiae Fructus[J]. Jilin Journal of Chinese Medicine, 2019, 39(2): 177-180.
    [16]
    史攀博, 李亨达, 薛宁, 等. 附子药理、毒理及解毒机制研究述评[J]. 中医学报, 2023, 38(11): 2347-2353.

    SHI P B, LI H D, XUE N, et al. Study Review of Pharmacology, Toxicology and Detoxification Mechanisms of Fuzi(Aconite)[J]. Acta Chinese Medicine, 2023, 38(11): 2347-2353.
    [17]
    李婷, 张晓乐, 倪文超, 等. 附子古今用量变化浅析[J]. 河南中医, 2022, 42(1): 26-28.

    LI T, ZHANG X L, NI W C, et al. An Analysis of the Change of Dosage of Fuzi in Ancient and Modern Times[J]. Henan Traditional Chinese Medicine, 2022, 42(1): 26-28.
    [18]
    陈劭赓, 何荣琦, 张万飞, 等. miR-122-5p通过靶向CREB1抑制食管癌细胞及移植瘤的生长[J]. 中国癌症杂志, 2021, 31(1): 35-44.

    CHEN S G, HE R Q, ZHANG W F, et al. miR-122-5p inhibits the growth of esophageal cancer cells and transplanted tumors by targeting CREB1[J]. China Oncology, 2021, 31(1): 35-44.
    [19]
    赵玉升, 胡杰, 吴佳姝, 等. 苦杏仁炮制方法及药理作用研究进展[J]. 中医药导报, 2021, 27(3): 175-180.

    ZHAO Y S, HU J, WU J S, et al. Research Progress on Processing Methods and Pharmacological Effects of Kuxingren (Armeniacae Semen Amarum)[J]. Guiding Journal of Traditional Chinese Medicine and Pharmacy, 2021, 27(3): 175-180.
    [20]
    韦宇, 赵林华, 邸莎, 等. 苦杏仁临床应用及其用量[J]. 吉林中医药, 2019, 39(11): 1456-1459.

    WEI Y, ZHAO L H, DI S, et al. Clinical Application and Dosage of Bitter Almond[J]. Jilin Journal of Chinese Medicine, 2019, 39(11): 1456-1459.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (9) PDF downloads(1) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return